1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Drugs In Development, 2022, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Wilson Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Wilson Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Wilson Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Wilson Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 4 and 7 respectively.
Wilson Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Wilson Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Wilson Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wilson Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wilson Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wilson Disease (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wilson Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wilson Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Wilson Disease - Overview
- Wilson Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Wilson Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Wilson Disease - Companies Involved in Therapeutics Development
- Alexion Pharmaceuticals Inc
- ARBORMED Pharmaceuticals Inc
- Deep Genomics Inc
- DepYmed Inc
- Enveda Biosciences Inc
- Generation Bio Co
- Krisani Bio Sciences Pvt Ltd
- LambdaGen Therapeutics
- Logicbio Therapeutics Inc
- MeiraGTx Holdings Plc
- Shanghai Pharmaceuticals Holding Co Ltd
- Ultragenyx Pharmaceutical Inc
- Vivet Therapeutics SAS
- Wilson Disease - Drug Profiles
- DG-12P1 - Drug Profile
- Product Description
- Mechanism Of Action
- DPM-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Wilson’s Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate ATP7B for Wilson Disease - Drug Profile
- Product Description
- Mechanism Of Action
- KBHD-001 - Drug Profile
- Product Description
- Mechanism Of Action
- methanobactin - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Wilson Disease - Drug Profile
- Product Description
- Mechanism Of Action
- SRD-3308 - Drug Profile
- Product Description
- Mechanism Of Action
- tiomolibdate choline - Drug Profile
- Product Description
- Mechanism Of Action
- UX-701 - Drug Profile
- Product Description
- Mechanism Of Action
- VTX-801 - Drug Profile
- Product Description
- Mechanism Of Action
- Wilson Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Wilson Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Wilson Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Wilson Disease - Dormant Projects
- Wilson Disease - Product Development Milestones
- Featured News & Press Releases
- Jun 23, 2022: ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson Disease community
- May 23, 2022: DepYmed receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the treatment of Wilson Disease
- Aug 27, 2021: Alexion’s drug meets primary goal in Phase III Wilson disease trial
- Jun 27, 2018: Progress toward improved Wilson's disease drug
- Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology
- Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
- Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting
- Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
- Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease
- Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease
- Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting
- Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
- Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting
- Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
- Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Wilson Disease, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Wilson Disease - Pipeline by Alexion Pharmaceuticals Inc, 2022
- Wilson Disease - Pipeline by ARBORMED Pharmaceuticals Inc, 2022
- Wilson Disease - Pipeline by Deep Genomics Inc, 2022
- Wilson Disease - Pipeline by DepYmed Inc, 2022
- Wilson Disease - Pipeline by Enveda Biosciences Inc, 2022
- Wilson Disease - Pipeline by Generation Bio Co, 2022
- Wilson Disease - Pipeline by Krisani Bio Sciences Pvt Ltd, 2022
- Wilson Disease - Pipeline by LambdaGen Therapeutics, 2022
- Wilson Disease - Pipeline by Logicbio Therapeutics Inc, 2022
- Wilson Disease - Pipeline by MeiraGTx Holdings Plc, 2022
- Wilson Disease - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
- Wilson Disease - Pipeline by Ultragenyx Pharmaceutical Inc, 2022
- Wilson Disease - Pipeline by Vivet Therapeutics SAS, 2022
- Wilson Disease - Dormant Projects, 2022
- Number of Products under Development for Wilson Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alexion Pharmaceuticals Inc
- ARBORMED Pharmaceuticals Inc
- Deep Genomics Inc
- DepYmed Inc
- Enveda Biosciences Inc
- Generation Bio Co
- Krisani Bio Sciences Pvt Ltd
- LambdaGen Therapeutics
- Logicbio Therapeutics Inc
- MeiraGTx Holdings Plc
- Shanghai Pharmaceuticals Holding Co Ltd
- Ultragenyx Pharmaceutical Inc
- Vivet Therapeutics SAS
